Labcorp Holdings Inc. (FRA:N6B)
Germany · Delayed Price · Currency is EUR | Market Cap | 21.71B +21.5% |
| Revenue (ttm) | 12.27B +7.3% |
| Net Income | 816.56M +28.8% |
| EPS | 9.79 +30.2% |
| Shares Out | n/a |
| PE Ratio | 26.59 |
| Forward PE | 16.46 |
| Dividend | 2.47 (0.96%) |
| Ex-Dividend Date | May 29, 2026 |
| Volume | n/a |
| Open | 262.00 |
| Previous Close | 258.00 |
| Day's Range | 262.00 - 262.00 |
| 52-Week Range | 212.00 - 262.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About Labcorp Holdings
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseas... [Read more]
Financial Performance
In 2025, Labcorp Holdings's revenue was $13.95 billion, an increase of 7.25% compared to the previous year's $13.01 billion. Earnings were $876.50 million, an increase of 17.49%.
Financial numbers in USD Financial StatementsNews
Labcorp launches Marker by Labcorp Genetic Health Panel
Labcorp (LH) announced the launch of Marker by Labcorp Genetic Health Panel, a new offering designed to help consumers better understand inherited risks associated with more than 100 medically actiona...
Labcorp Launches Marker by Labcorp™ Genetic Health Panel, Expanding Consumer Access to Hereditary Genetic Risk Testing
New offering analyzes 163 genes linked to more than 100 medically actionable conditions Includes genetic counseling support to help consumers understand results and take informed next steps Consumers ...
Labcorp awarded $364.7M Defense Health Agency contract
Labcorp (LH) was awarded $364.7M for a single-award, indefinite delivery/indefinite quantity contract utilizing firm-fixed-price task orders to provide the Defense Health Agency with commercial clinic...
HCA preannouncement negative for Quest, Labcorp, says Barclays
Barclays views HCA Healthcare’s (HCA) preannouncement on Affordable Care Act coverage lost during Q2 is a negative read-through for Quest Diagnostics (DGX) and Labcorp (LH). HCA’s Affordable Care Act ...
Labcorp price target raised to $320 from $300 at BofA
BofA analyst Michael Ryskin raised the firm’s price target on Labcorp (LH) to $320 from $300 and keeps a Buy rating on the shares as part of the firm’s Q2…
Labcorp Declares Quarterly Dividend
BURLINGTON, N.C., July 9, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has de...
Labcorp to Announce Second Quarter 2026 Financial Results on July 30, 2026
BURLINGTON, N.C., June 30, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second...
Labcorp announces nationwide availability of ColoSense
Labcorp (LH) announced the nationwide availability of ColoSense, the only RNA-based at-home test for colorectal cancer screening approved by the U.S. FDA. Offered through a commercial collaboration wi...
Labcorp Announces Nationwide Availability of ColoSense®, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening Test
First FDA-approved, at-home screening test that uses RNA technology to detect biomarkers associated with colorectal cancer and advanced adenomas Designed to reduce common barriers to at-home screening...
Labcorp Holdings Transcript: Jefferies Global Healthcare Conference 2026
Strong Q1 results led to raised full-year guidance, with growth driven by diagnostics, specialty testing, and consumer-initiated channels. AI and innovation are central to operational efficiency and portfolio expansion, while M&A targets regional labs and health systems for strategic growth.
Labcorp announces collaboration with Alliance for Clinical Trials in Oncology
Labcorp (LH) announced a collaboration with the Alliance for Clinical Trials in Oncology to advance a national, multicenter clinical trial for patients newly diagnosed with colorectal cancer. The tria...
Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer
Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members Research will also assess the clinical ...
Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects
New pharmacogenomic test detects all DPYD variants recommended by the Association for Molecular Pathology to support safer, more personalized cancer treatment BURLINGTON, N.C., May 28, 2026 /PRNewswir...
Labcorp to Present at the Jefferies Global Healthcare Conference
BURLINGTON, N.C., May 27, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that the company will present at the 2026 Jeffer...
Labcorp Holdings Transcript: AGM 2026
The meeting covered strong 2025 financial results, board elections, executive compensation, and auditor ratification, with all proposals passing by wide margins. Management addressed regulatory risks in animal research supply chains and affirmed operational resilience.
Labcorp Launches MyLabcorp™, a New AI-Powered Mobile App Designed to Help Consumers Understand Lab Results and Track Health Trends Over Time
MyLabcorp connects lab results, educational content and AI-enabled features in a secure, personalized mobile experience Leverages OpenAI models designed to help users understand their results, ask que...
Labcorp, Epic expand collaboration
Labcorp (LH) announced an expanded collaboration with Epic, the nation’s leading electronic health record supporting hospitals and health systems. Through the collaboration, Labcorp’s full test menu w...
Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems
Labcorp's full test menu will be available through Epic's Aura platform Integration builds on the successful deployment of Invitae genetic testing and accelerates access to the latest genetic and spec...
Labcorp price target raised to $334 from $332 at Baird
Baird analyst Eric Coldwell raised the firm’s price target on Labcorp (LH) to $334 from $332 and keeps an Outperform rating on the shares. The firm updated its model following…
Labcorp reports Q1 adjusted EPS $4.25, consensus $4.12
Reports Q1 revenue $3.54B, consensus $3.51B. “Labcorp (LH) delivered another quarter of strong results, with robust growth and double-digit Adjusted EPS growth driven by continued momentum across our ...
Labcorp raises FY26 adjusted EPS view to $17.70-$18.35 from $17.55-$18.25
Consensus $17.79. Raises FY26 revenue view to $14.65B-$14.8B from $14.61B-$14.79B, consensus $14.67B. The company said, “Labcorp (LH) is updating 2026 full year guidance to reflect its first quarter p...
Labcorp Holdings Earnings Call Transcript: Q1 2026
Q1 2026 delivered 5.8% revenue growth, 10.6% EPS growth, and margin expansion, driven by strong Diagnostics and BLS performance, specialty testing, and strategic partnerships. Guidance for 2026 was raised, with continued focus on innovation, M&A, and operational efficiency.
Labcorp Holdings Earnings release: Q1 2026
Labcorp Holdings released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Labcorp Holdings Slides: Q1 2026
Labcorp Holdings has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 30, 2026.
Labcorp Holdings Quarterly report: Q1 2026
Labcorp Holdings has published its Q1 2026 quarterly earnings report on April 30, 2026.